ATS Urges Medicare to Allow Coverage of Phrenic Nerve Stimulation for Central Sleep Apnea
The ATS submitted comments to National Government Services (NGS), a Medicare Administrative Contractor, regarding the current restrictive coverage of phrenic nerve stimulation for the treatment of central sleep apnea. Currently, NGS views phrenic nerve stimulation as experimental and will not reimburse Medicare providers for the treatment. The ATS noted new randomized control trials have demonstrated the safety and efficacy of phrenic nerve stimulation in carefully selected patients and urged NGS to revise their coverage policy to include phrenic nerve stimulation for treatment of central sleep apnea.
Last Reviewed: March 2021
